« Top Headlines » Open DEMAT Account in 24 hrs  Mock Test Papers Series - I & II for Students appearing in CA Foundation January 2027 Examination.  Income Tax Rules 2026: CBDT Introduces Revised Form 161 for Penalty Waiver, Clarifies Misreporting Categories and Taxpayer Relief  ITR Filing and Income Tax Audit Deadline Extended: 5 Critical Things Taxpayers Must Know  Filing Belated ITR for AY 2026-27? Know Which Losses You Can Carry Forward and Which You May Lose  CBDT Extends Tax Audit Report Deadline to October 21, ITR Filing Last Date to November 21 for AY 2026-27  CBDT Extends AY 2026-27 ITR Filing Deadline for Tax-Audit Cases: New Dates and Key Compliance Details  Foreign Assets Missing From Your ITR? Income Tax Department Opens One-Time Disclosure Window  Tax Audit Deadline September 30: Why AIS, TDS and GST Figures May Not Match Your ITR and What Taxpayers Should Do  Tax audit deadline September 30: Common mistakes taxpayers should avoid  Your ITR says ‘verified’, but the refund hasn’t arrived? 5 reasons why your money could be stuck  Missed the ITR Deadline but TDS Refund Is Due? Here’s How You Can Still Claim Your Money «  Telecom industry for tax holiday... HC notice to finmin over non-CA tax preparers... » Cabinet to look into amendment November, 21st 2006 In a move that will boost the pharmaceutical sector, the Cabinet Committee on World Trade Organisation is expected to take up a proposal for amending the compulsory license clause in the Trade-Related Intellectual Property Rights (TRIPS) agreement.    Once this decision is taken, the Centre will propose to WTO to waive off the obligation under Article 31(f) and Article 31(h) of the TRIPS agreement, so that it can directly export pharma products to countries having insufficient or no manufacturing capacity.    Under the current circumstances, a government has an exceptional provision of allowing a pharma company to produce the patented product or process without the consent of the patent owner in case of a medical emergency.    But if the article is relaxed for India, domestic companies will be able to export the products to other countries in case of national emergencies without the authorisation of the patent holder.    Article 31(h) of TRIPS specifies that the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorisation benefit.